全球幹細胞檢測市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計幹細胞檢測市場將從 2025 年的 23.8 億美元成長到 2034 年的 51.7 億美元，2026 年至 2034 年的複合年成長率為 9.01%。

幹細胞檢測市場正迅速擴張，這主要得益於再生醫學、藥物研發和毒性測試領域的投資不斷成長。基於幹細胞的檢測方法能夠建構生理相關的疾病模型、療效篩檢和安全性評估模型，從而減少對動物模型的依賴。誘導多功能細胞 (iPSC) 技術、類器官和高內涵成像技術的進步進一步推動了這一成長，使研究人員能夠在體外研究類人組織和複雜的細胞間相互作用。

關鍵促進因素包括製藥業對預測人體反應的更優轉化模型的需求、監管機構鼓勵採用動物試驗以外的替代方法，以及幹細胞分化通訊協定的學術突破。將幹細胞與微流體技術、3D培養和自動化篩檢相結合的平台技術提高了通量和可重複性。受託研究機構和生技公司擴大將幹細胞檢測工作外包，推動了市場服務和耗材收入的成長。

展望未來，隨著標準化、檢測方法檢驗和法規核准的推進，市場可望成熟。推動這一成長的主要動力是患者來源的誘導多能幹細胞（iPS細胞）在個人化醫療中的應用，以及它們與CRISPR基因編輯技術在標靶檢驗方面的整合。此外，安全藥理學、再生醫學開發和疾病模型建構等領域的合作研究的商業機會也預計將擴大。解決檢測方法的可重複性、擴充性和成本限制將是實現產業和法規環境廣泛應用的關鍵。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球幹細胞檢測市場：依產品分類

• 市場分析、洞察與預測
• 裝置
• 試劑和試劑盒
• 軟體

第5章 全球幹細胞檢測市場：按類型分類

• 市場分析、洞察與預測
• 細胞活力和毒性檢測
• 細胞鑑定分析
• 細胞生長化驗
• 細胞分化實驗
• 其他

第6章 全球幹細胞檢測市場：依應用分類

• 市場分析、洞察與預測
• 再生醫學和治療方法研發
• 藥物發現與開發
• 臨床研究
• 其他

第7章 全球幹細胞檢測市場：依最終用戶分類

• 市場分析、洞察與預測
• 生物技術和製藥公司
• 學術研究機構
• 其他

第8章 全球幹細胞檢測市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第9章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第10章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Thermo Fisher Scientific
  • Merck KGaA
  • GE Healthcare
  • Bio-Rad Laboratories
  • Promega Corporation
  • Agilent Technologies
  • PerkinElmer
  • Lonza Group
  • Cell Biolabs
  • Stemcell Technologies
  • R&D Systems

The Stem Cell Assays Market size is expected to reach USD 5.17 Billion in 2034 from USD 2.38 Billion (2025) growing at a CAGR of 9.01% during 2026-2034.

The stem cell assays market has expanded rapidly with increased investment in regenerative medicine, drug discovery, and toxicology testing. Stem cell-based assays enable physiologically relevant models for disease modeling, efficacy screening, and safety profiling, reducing reliance on animal models. Growth has been catalyzed by advances in induced pluripotent stem cell (iPSC) technologies, organoids, and high-content imaging, which allow researchers to study human-like tissues and complex cellular interactions in vitro.

Primary drivers include pharmaceutical industry demand for better translational models to predict human responses, regulatory encouragement for alternatives to animal testing, and academic breakthroughs in stem cell differentiation protocols. Platform technologies combining stem cells with microfluidics, 3D culture, and automated screening enhance throughput and reproducibility. Contract research organizations and biotech companies increasingly outsource stem-cell assay work, boosting market services and consumables revenue.

Looking forward, the market is poised for maturation as standardization, assay validation, and regulatory acceptance improve. Expansion will be driven by personalized medicine applications-using patient-derived iPSCs-and integration with CRISPR gene-editing for target validation. Commercial opportunities in safety pharmacology, regenerative-therapeutic development, and disease-modeling collaborations will grow. Addressing assay reproducibility, scalability, and cost constraints will be key to broader adoption across industry and regulatory settings.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• Instruments
• Reagents & Kits
• Software

By Type

• Cell Viability & Toxicity Assays
• Cell Identification Assays
• Cell Proliferation Assays
• Cell Differentiation Assays
• Others

By Application

• Regenerative Medicine & Therapy Development
• Drug Discovery & Development
• Clinical Research
• Others

By End-User

• Biotechnology & Pharmaceutical Companies
• Academic & Research Institutes
• Others

COMPANIES PROFILED

• Thermo Fisher Scientific, Merck KGaA, GE Healthcare, BioRad Laboratories, Promega Corporation, Agilent Technologies, PerkinElmer, Lonza Group, Cell Biolabs, Stemcell Technologies, RD Systems
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL STEM CELL ASSAYS MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Instruments Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Reagents & Kits Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Software Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL STEM CELL ASSAYS MARKET: BY TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Type
• 5.2. Cell Viability & Toxicity Assays Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Cell Identification Assays Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Cell Proliferation Assays Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Cell Differentiation Assays Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL STEM CELL ASSAYS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Regenerative Medicine & Therapy Development Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Drug Discovery & Development Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Clinical Research Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL STEM CELL ASSAYS MARKET: BY END-USER 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End-user
• 7.2. Biotechnology & Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Academic & Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL STEM CELL ASSAYS MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Product
  • 8.2.2 By Type
  • 8.2.3 By Application
  • 8.2.4 By End-user
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Product
  • 8.3.2 By Type
  • 8.3.3 By Application
  • 8.3.4 By End-user
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Product
  • 8.4.2 By Type
  • 8.4.3 By Application
  • 8.4.4 By End-user
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Product
  • 8.5.2 By Type
  • 8.5.3 By Application
  • 8.5.4 By End-user
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Product
  • 8.6.2 By Type
  • 8.6.3 By Application
  • 8.6.4 By End-user
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL STEM CELL ASSAYS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Thermo Fisher Scientific
  • 10.2.2 Merck KGaA
  • 10.2.3 GE Healthcare
  • 10.2.4 Bio-Rad Laboratories
  • 10.2.5 Promega Corporation
  • 10.2.6 Agilent Technologies
  • 10.2.7 PerkinElmer
  • 10.2.8 Lonza Group
  • 10.2.9 Cell Biolabs
  • 10.2.10 Stemcell Technologies
  • 10.2.11 R&D Systems